Welcome to our dedicated page for Chrome Holding Co news (Ticker: MEHCQ), a resource for investors and traders seeking the latest updates and insights on Chrome Holding Co stock.
MEHCQ represents the public equity of 23andMe Holding Co., later identified in SEC filings as Chrome Holding Co., a genetics-led consumer healthcare and biotechnology company that entered Chapter 11 proceedings and pursued a court-supervised sale of substantially all of its assets. The news flow around MEHCQ focuses on restructuring developments, asset sale milestones, and the transition of the company’s operating businesses to a nonprofit acquirer.
Company announcements describe 23andMe as a genetics-led consumer healthcare and biotechnology company with a mission to help people access, understand and gain health benefits through greater understanding of the human genome. News releases detail the sale of the Personal Genome Service (PGS) and Research Services business lines and the Lemonaid Health business to TTAM Research Institute, a nonprofit public benefit corporation based in California that later appears in SEC filings as 23andMe Research Institute. Earlier communications also reference a definitive agreement with Regeneron Pharmaceuticals, Inc. before TTAM was selected as the winning bidder in a final round of bidding supervised by the bankruptcy court.
Visitors to the MEHCQ news page can review coverage of key events such as the initiation of voluntary Chapter 11 cases in the United States Bankruptcy Court for the Eastern District of Missouri, the announcement and approval of the Section 363 sale, and the completion of the transaction with TTAM Research Institute. Additional news items describe the company’s intent to voluntarily delist from Nasdaq via a Form 25 filing and to deregister with the SEC via a Form 15, as well as detailed statements on customer data protections, privacy commitments, and the role of independent privacy oversight in the sale process.
This news archive is useful for investors, creditors, and observers who want to follow how a genetics-led consumer healthcare and biotechnology company managed its Chapter 11 restructuring, asset sale, and transition of its consumer genetics and research operations to a nonprofit public benefit corporation. By reading through the sequence of press releases, users can trace the evolution of the sale process, the competitive bidding between potential acquirers, and the privacy and data protection conditions attached to the transfer of customer data and services.
TTAM Research Institute, a California-based nonprofit public benefit corporation led by Anne Wojcicki, has completed the acquisition of 23andMe's (OTC: MEHCQ) Personal Genome Service (PGS) and Research Services business lines through a Section 363 bankruptcy sale.
The acquisition ensures the continuation of 23andMe's DNA testing and research services operations under TTAM's leadership. The nonprofit has committed to maintaining customer data transparency and choice, including the option for customers to modify their research participation preferences.
The transaction was executed as part of 23andMe's Chapter 11 bankruptcy proceedings, with multiple advisory firms supporting both parties throughout the process.
23andMe (OTC: MEHCQ) has secured U.S. Bankruptcy Court approval for the sale of substantially all its assets to TTAM Research Institute, a nonprofit public benefit corporation, for $305 million. The transaction, expected to close in the coming weeks, includes the Personal Genome Service (PGS), Research Services business lines, and Lemonaid Health business.
TTAM Research Institute, led by 23andMe Co-Founder and former CEO Anne Wojcicki, will operate as a nonprofit focused on advancing human genome research for public benefit. The institute has committed to maintaining 23andMe's existing privacy policies and implementing additional consumer protections and privacy safeguards.
As part of the transition, all customers will receive advance notice of the sale via email. The deal represents a significant milestone in 23andMe's Chapter 11 proceedings and aims to preserve the company's founding mission of helping people access and understand genetic information.
23andMe (OTC: MEHCQ) has announced its intention to voluntarily delist from Nasdaq and deregister with the SEC. The company plans to file a Form 25 Notification of Delisting around June 6, 2025. This follows Nasdaq's suspension of 23andMe's Class A common stock trading on March 31, 2025. The delisting action comes after the company and its subsidiaries initiated voluntary Chapter 11 bankruptcy proceedings on March 23, 2025 in the U.S. Bankruptcy Court for the Eastern District of Missouri. Following the effectiveness of the Nasdaq delisting, 23andMe intends to file a Form 15 to complete its SEC deregistration.
23andMe (OTC: MEHCQ) has provided an update on its court-supervised asset sale process and customer data protection measures. The company's Special Committee will evaluate acquisition bids under U.S. Bankruptcy Court supervision. Key highlights:
- No bids will be accepted from entities based in or controlled by countries of concern (China, Cuba, Iran, North Korea, Russia, Venezuela)
- Bidders must guarantee compliance with company privacy policies and laws
- Potential bidders must detail intended use of customer data and privacy programs
- Company has filed motion to appoint independent Customer Data Representative (CDR) to review transaction compliance
The process requires regulatory approvals, including Hart-Scott-Rodino Act and Committee on Foreign Investment reviews. 23andMe maintains strict data privacy protocols and operates under consumer and genetic privacy laws.